0000905718-16-001361.txt : 20160421 0000905718-16-001361.hdr.sgml : 20160421 20160421161958 ACCESSION NUMBER: 0000905718-16-001361 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20160421 DATE AS OF CHANGE: 20160421 EFFECTIVENESS DATE: 20160421 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Variant Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001613083 IRS NUMBER: 465188564 STATE OF INCORPORATION: FL FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-261821 FILM NUMBER: 161584259 BUSINESS ADDRESS: STREET 1: 2200 N. COMMERCE PARKWAY STREET 2: SUITE 200 CITY: WESTON STATE: FL ZIP: 33326 BUSINESS PHONE: 954-931-2075 MAIL ADDRESS: STREET 1: 2200 N. COMMERCE PARKWAY STREET 2: SUITE 200 CITY: WESTON STATE: FL ZIP: 33326 D 1 primary_doc.xml X0707 D LIVE 0001613083 Variant Pharmaceuticals, Inc. 2200 N. COMMERCE PARKWAY SUITE 200 WESTON FL FLORIDA 33326 954-931-2075 FLORIDA None None Corporation true 2014 Stephen C Glover 2200 N. COMMERCE PARKWAY SUITE 200 WESTON FL FLORIDA 33326 Executive Officer Director Shawn M Titcomb 2200 N. COMMERCE PARKWAY SUITE 200 WESTON FL FLORIDA 33326 Director Nico Pronk 2200 N. COMMERCE PARKWAY SUITE 200 WESTON FL FLORIDA 33326 Director Aaron Greenblatt 2200 N. COMMERCE PARKWAY SUITE 200 WESTON FL FLORIDA 33326 Director Pharmaceuticals Decline to Disclose 06b false true false true true Convertible Promissory Notes false 0 Craft Capital Management LLC 171350 None None 377 OAK STREET STE. 402 GARDEN CITY NY NEW YORK 11530 CA CALIFORNIA CT CONNECTICUT FL FLORIDA GA GEORGIA ID IDAHO IL ILLINOIS IN INDIANA IA IOWA KS KANSAS KY KENTUCKY LA LOUISIANA MD MARYLAND MI MICHIGAN MN MINNESOTA MS MISSISSIPPI MO MISSOURI MT MONTANA NE NEBRASKA NV NEVADA NY NEW YORK NC NORTH CAROLINA ND NORTH DAKOTA OH OHIO OK OKLAHOMA OR OREGON PA PENNSYLVANIA SC SOUTH CAROLINA SD SOUTH DAKOTA TX TEXAS UT UTAH VA VIRGINIA WA WASHINGTON WI WISCONSIN WY WYOMING false 2000000 0 2000000 false 0 160000 true 0 true Assumes maximum offering sold by Craft Capital Management LLC. Excludes warrants to purchase up to 13,333 shares at an exercise price of $3.00 per share as set forth in the offering documents. 0 true Some of the proceeds will be used for general working capital purposes which may include the payment of salaries and other fees to those listed in Item 3. false Variant Pharmaceuticals, Inc. /s/ Stephen C. Glover Stephen C. Glover CEO 2016-04-21